Complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the Leishmania metabolome caused by miltefosine by Armitage, Emily G. et al.
1 
 
A complex interplay between sphingolipid and sterol metabolism revealed by 1 
perturbations to the Leishmania metabolome caused by miltefosine 2 
Emily G. Armitage1,2,3, Amjed Q. I. Alqaisi4,5, Joanna Godzien1, Imanol Peña2, Alison J. Mbekeani4, 3 
Vanesa Alsonso-Herranz1, Ángeles López-Gonzálvez1, Julio Martín2, Raquel Gabarro2, Paul W. 4 
Denny4*, Michael P. Barrett3* and Coral Barbas1* 5 
 6 
1. Centre for Metabolomics and Bioanalysis (CEMBIO), Facultad de Farmacia, Universidad CEU San Pablo, 7 
Campus Montepríncipe, Boadilla del Monte, 28668 Madrid, Spain  8 
 9 
2. GSK I+D Diseases of the Developing World (DDW), Parque Tecnológico de Madrid, Calle de Severo Ochoa 2, 10 
28760 Tres Cantos, Madrid, Spain  11 
 12 
3. Wellcome Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of 13 
Medical, Veterinary and Life Sciences & Glasgow Polyomics, University of Glasgow, Glasgow, UK 14 
 15 
4. Department of Biosciences, Durham University, Lower Mountjoy, Stockton Road, Durham, DH1 3LE, UK 16 
 17 
5. University of Baghdad, College of Science, Biology Department, Baghdad, Iraq 18 
 19 
Running title: Miltefosine on sphingolipids and sterols in Leishmania 20 
* Correspondence during publication process to Professor Coral Barbas:  cbarbas@ceu.es 21 
* Correspondence once published to cbarbas@ceu.es, Michael.Barrett@glasgow.ac.uk and  22 
p.w.denny@durham.ac.uk  23 
 24 
AAC Accepted Manuscript Posted Online 20 February 2018
Antimicrob. Agents Chemother. doi:10.1128/AAC.02095-17
Copyright © 2018 Armitage et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
 o
n
 M
arch 20, 2018 by SW
ETS SUBSCRIPTIO
N SERVICE
http://aac.asm
.org/
D
ow
nloaded from
 
2 
 
ABSTRACT 25 
With the World Health Organization reporting over 30,000 deaths and 200-400,000 new cases 26 
annually, visceral Leishmaniasis is a serious disease affecting some of the world's poorest people.  As 27 
drug resistance continues to rise, there is a huge unmet need to improve treatment. Miltefosine 28 
remains one of the main treatments for Leishmaniasis, yet its mode of action (MoA) is still unknown. 29 
Understanding the MoA of this drug and parasite response to treatment could help pave the way for 30 
new, more successful treatments for Leishmaniasis. A novel method has been devised to study the 31 
metabolome and lipidome of Leishmania donovani axenic amastigotes treated with miltefosine. 32 
Miltefosine caused a dramatic decrease in many membrane phospholipids (PLs), in addition to 33 
amino acid pools, while sphingolipids (SLs) and sterols increased. Leishmania major promastigotes 34 
devoid of SL biosynthesis through loss of the serine palmitoyl transferase gene (∆LCB2) were 3-fold 35 
less sensitive to miltefosine than WT parasites. Changes in the metabolome and lipidome of 36 
miltefosine treated L. major mirrored those of L. donovani.  A lack of SLs in the ∆LCB2 was matched 37 
by substantial alterations in sterol content. Together these data indicate that SLs and ergosterol are 38 
important for miltefosine sensitivity and perhaps, MoA.  39 
 40 
INTRODUCTION 41 
Infectious diseases continue to cause great morbidity and mortality worldwide(1). New drugs are 42 
required and will need to be continuously replenished as resistance to antimicrobials increases. 43 
Understanding the mode of action (MoA) of currently available treatments against microbial 44 
diseases offers a means to highlight targets for new treatments. Metabolomics plays an important 45 
role in this discovery and development of new medicines for infectious diseases(1). 46 
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The Leishmaniases are a spectrum of neglected tropical diseases caused by protozoa of the genus 47 
Leishmania. Individual species provoke different clinical manifestations including visceral 48 
Leishmaniasis caused by Leishmania donovani and Leishmania infantum(2) which is fatal if not 49 
treated. Existing therapeutic options are limited(3), so the search for alternative therapies continues. 50 
Two key developmental stages of Leishmania: amastigotes and more commonly promastigotes are 51 
used for in vitro studies of drug MoA. Promastigotes are the form found in the sand fly vector, while 52 
amastigotes exist in the mammalian host. Development of axenic cultures, having physiological 53 
similarity to the macrophage resident forms in mammalian infections, has made it possible to study 54 
amastigotes in vitro(2). 55 
Metabolomics seeks comprehensive measurements of small molecules in a given system. However, 56 
the dynamic range in abundance and broad physicochemical diversity of metabolites is such that a 57 
single analytical platform is lacking. Here, a combined liquid chromatography – mass spectrometry 58 
(LC-MS) and capillary electrophoresis – mass spectrometry (CE-MS) approach was used to increase 59 
coverage of the Leishmania metabolome and applied to study MoA of miltefosine, the first drug 60 
approved for oral treatment of Leishmaniasis. Metabolomics has proven useful in drug MoA studies 61 
for Leishmania promastigotes(4–13), but so far not for L. donovani amastigotes. L. mexicana 62 
amastigotes were recently studied using metabolomics to show that amastigote differentiation is 63 
associated with the induction of a distinct stringent metabolic state(14), in both lesion-derived and 64 
in vitro differentiated amastigotes.  65 
Several suggestions have been made regarding the anti-leishmanial action of miltefosine: induction 66 
of apoptosis-like death(15, 16), or disruption of metabolite transport(4, 17, 18). The uptake of 67 
miltefosine in Leishmania is dependent on transmembrane lipid transporters, most notably the 68 
flippase LdMT and its accessory protein – LdRos that are commonly lost with selection of 69 
resistance(19). More recently, using cosmid-based functional cloning coupled to next-generation 70 
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sequencing, genes involved in ergosterol biosynthesis and phospholipid (PL) translocation were 71 
suggested to contribute to resistance in L. infantum(20). 72 
Metabolomic analyses of miltefosine treated L. infantum showed a general depletion of intracellular 73 
metabolites(6) and similar studies in other Leishmania demonstrated lipid remodelling(21–24). 74 
Biochemical modifications to different lipid classes have been reported in the membranes of 75 
miltefosine treated L .donovani promastigotes(22). In addition to diminishing phosphatidylcholine 76 
(PC), miltefosine was found to double sterol composition too(22). Effects of miltefosine treatment 77 
on lipid metabolism in promastigotes of L. infantum(6) have also been observed using 78 
metabolomics, although only lipid class rather than individual lipid species were resolved. Combining 79 
CE-MS to analyse polar and ionic metabolites and reversed phase LC-MS to reveal specific lipidomic 80 
changes in L .donovani has allowed a more detailed analysis into the MoA in axenic amastigotes 81 
presented herein.    82 
Substantial changes in sphingolipid (SL) and sterol metabolism were revealed in miltefosine treated 83 
L. donovani promastigotes. SLs were first reported in L. donovani more than 20 years ago(25) and 84 
along with sterols, have since received attention in many species(26–28). Leishmania obtain SLs via 85 
salvage or de novo synthesis(29), and they play important roles in differentiation, replication, 86 
trafficking and virulence(29). The prominent, and most studied, SL identified is inositol 87 
phosphoceramide (IPC), although Leishmania are believed to exhibit a complete and functional SL 88 
pathway involving both biosynthesis and degradation(28, 30). A more comprehensive analysis of 89 
different SLs may identify other key targets of SL metabolism for therapy. To study the viability of 90 
Leishmania without SL synthesis, a mutant was created by deletion of the gene encoding the 91 
essential catalytic subunit of the serine palmitoyltransferase (ΔLCB2), the first and rate-limiting step 92 
in SL biosynthesis(28, 31). Surprisingly, this mutant was viable, indicating a dispensable role for SLs in 93 
Leishmania, unlike in the related parasite Trypanosoma brucei(32). It was suggested that the sterol 94 
composition of the Leishmania plasma membrane, where ergosterol replaces cholesterol as the 95 
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primary membrane sterol, could enable this(32). Here perturbations to Leishmania SL and sterol 96 
metabolism on miltefosine treatment are described, the interplay between these metabolite 97 
families is considered and the role sterols play in drug sensitivity proposed.  98 
RESULTS AND DISCUSSION 99 
In order to define the optimal protocol for sampling/quenching/extracting/analysing metabolites 100 
from L. donovani axenic amastigotes, a method was developed as described below and further in the 101 
Supplementary Information (SI - file 1). The extraction procedure was optimised such that LC-MS and 102 
CE-MS analyses could be performed from single samples of as few as 1 × 107 parasites (SI Figure 1S:). 103 
For L. donovani, samples were treated with 4.47 μM (the observed EC50 at 72 hours, consistent with 104 
the literature (33)) or 13.41 μM (three times the observed EC50 at 72 hours) miltefosine and 105 
harvested after 5h or 24h of exposure to observe the initial effects of the drug. For L. major, samples 106 
were treated with 10 μM or 30 μM miltefosine and harvested after 5h of exposure. DMSO controls 107 
were prepared alongside treated samples at each time-point for both species. Results from method 108 
development stages are detailed in the SI, where a comparison of methanol extraction and a more 109 
comprehensive extraction for lipidomics using LC-MS is shown in figure 2S, profiles obtained using 110 
LC-MS and CE-MS analysis of different extractions are shown in figure 3S and the final optimised 111 
dual extraction procedure to obtain different extracts for LC-MS and CE-MS analysis from single 112 
samples is shown in figure 4S.  113 
Metabolomic determination of Leishmania response to miltefosine  114 
With the exception of the aforementioned work on L. mexicana amastigotes(14), the few studies on 115 
drug MoA in Leishmania have focussed on the promastigote form(2–10). The aim of this research 116 
was to explore effects on metabolism of miltefosine in L. donovani axenic amastigotes and, as a 117 
result of these findings, in L. major promastigotes.  118 
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After verification of quality (SI Figure 5S), data were divided into separate sets and differences 119 
between treated and untreated parasites identified. Around 20 metabolites, including the drug 120 
itself, were detected only in treated samples. These features, listed after the supplementary tables 121 
in supplementary information, were all found to elute with the drug and therefore most likely 122 
enhanced by the ionisation of the drug. These could not be identified as endogenous lipids and were 123 
therefore assumed to be mass spectrometry derivatives of the drug itself. All were removed prior to 124 
multivariate analysis to avoid separation based on presence or absence of drug alone. Identification 125 
was performed for metabolite features found to increase/decrease with treatment after 5 or 24 h of 126 
exposure, determined by a p-value <0.05 (Student’s two-tailed t-test, n=6 per group) and a fold 127 
change of ±1.5, calculated for at least one of the comparisons made. Identification of metabolites 128 
found by CE-MS was confirmed by injection of authentic standards (as detailed in Supplementary 129 
Table 1). Lipids detected using LC-MS were annotated considering chemical properties and elution 130 
order. Miltefosine treatment affected different metabolic classes and possible impact on MoA is 131 
discussed below, based on data presented in the Supplementary Tables (STs), a description for which 132 
is given in SI.  133 
L. donovani axenic amastigotes 134 
Miltefosine has been proposed to affect the transport of different metabolites(4, 17, 18). Consistent 135 
with previous literature(6), miltefosine induced decreases in the majority of internal metabolites 136 
detected by CE-MS, as shown in Table 1, which could be associated with impaired uptake. Figure 1 137 
shows the abundances of metabolites associated with arginine metabolism detected in this study. 138 
Arginine is a precursor to polyamine biosynthesis and a protein building block. Its intracellular 139 
concentration is controlled by dedicated sensory protein transporters(10, 18), which have been 140 
suggested as targets of miltefosine(4). Arginase, which catalyses the hydrolysis of arginine to 141 
ornithine, also contribute to the intracellular concentration of arginine. The co-ordinated decrease in 142 
arginine and ornithine may indicate a reduction in precursor levels (through blocking arginine 143 
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transport), a notion consistent with previously reported literature (34, 35). Another metabolite that 144 
shares the same mass but has a distinct migration time to citrulline was identified  as argininic acid 145 
which is considered an endpoint of arginine metabolism previously found in different Leishmania 146 
species, including L. donovani(36). Its concentration was substantially reduced with treatment at 147 
both time-points and doses (up to 3-fold) in this research. 148 
While data from CE-MS largely confirmed observations in the literature, the approach here has given 149 
a finer-grained view of the effect of miltefosine on lipids. Compared to mammals, Leishmania 150 
membrane lipids differ substantially in composition and function, making them important for 151 
viability and virulence as well as potential drug targets(29). Lipids have been analysed previously in L. 152 
donovani(7, 22, 29, 37), as have changes in lipid metabolism connected to miltefosine treatment(21–153 
23, 38, 39). Here we demonstrate more detail on individual lipid species than has previously been 154 
reported.    155 
In L. infantum, miltefosine was reported to alter 10 % of the metabolome, purportedly due to 156 
compromised outer membrane integrity leading to lysis(6). Here, a general decrease in membrane 157 
PL abundance was observed in L.donovani axenic amastigotes (see STs 2, 3 and 4 for specific lipids). 158 
Miltefosine was reported by Zufferey et al. (2002) to inhibit PC biosynthesis, diminishing levels in L. 159 
donovani promastigotes leading to growth arrest(21). Phospholipase D activity was unaffected by 160 
the drug, hence inhibition of the choline transporter was proposed to underlie the reduction in PC 161 
biosynthesis(21) . A number of PCs and other PLs were found diminished in this study too (ST2). 162 
Other considerable effects of treatment observed were increases in sterols and, to an even greater 163 
extent, SLs. To investigate this further, all filtered LC-MS data were scanned to identify peaks 164 
identifiable as SLs (even if the relative levels in treated and untreated parasites were not statistically 165 
different). Figure 2 shows the trends observed in SLs, where data are plotted for un-treated 166 
parasites and parasites treated with the lowest dose of miltefosine at 24 h. A dramatic and 167 
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significant (5-fold) increase in sphingosine abundance induced by miltefosine (p=2×10-6) was 168 
mirrored by a 3-fold increase in sphinganine (p=7×10-4). All detected ceramides were also 169 
substantially increased by 24 h, as shown and detailed in Supplementary Table 3.  170 
L. major promastigotes 171 
Leishmania SL metabolism has been best studied in the promastigote form of L. major, where a 172 
ΔLCB2 mutant lacking the first enzyme of the biosynthetic pathway, serine palmitoyl transferase,  is 173 
available(28, 31).  The effects of miltefosine in these L. major promastigotes were therefore 174 
investigated. The efficacy of miltefosine was established against both the ∆LCB2 mutant and wild 175 
type lines; the EC50 for the wild type was 6.83 µM, consistent with previous literature (33), whilst for 176 
mutant was three times higher at 21.21 µM. The lipidome of these parasites revealed major 177 
differences between the wild type and ∆LCB2 lines and the effect of miltefosine was also compared. 178 
Lipids identified with marked differences in abundance between any experimental groups compared 179 
are detailed in STs 5, 6 and 7. As in L. donovani, miltefosine itself and around 20 other features were 180 
detected only in treated samples. Miltefosine was identified in both wild type and ΔLCB2 mutant, 181 
with no significant difference in relative concentration (p=0.09 for the lower dose and p=0.45 at the 182 
higher dose). This demonstrated that the 3-fold resistance of the mutant was not due to inhibited 183 
import. As in L. donovani in this study and reported in L. infantum previously(6), miltefosine caused 184 
substantial effects in levels of numerous PLs in L.major too. This reduction may be due to reduced 185 
import of PLs or choline, or reduced de novo biosynthesis.  186 
Miltefosine’s effects on L. major SLs were similar to those observed after 24h of exposure in L. 187 
donovani amastigotes. Figure 3 shows the fold changes for both doses. As can be seen, some SLs 188 
were detected only in L .donovani or only in L .major. This may be due to species specific differences 189 
and could even be due to differences in the mechanism of each species given that they cause 190 
different forms of leishmaniasis (L. donovani causing the visceral form and L. major the cutaneous 191 
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form). The L. major ΔLCB2 mutants lack most SLs, in accordance with them being devoid of SL 192 
biosynthesis. Sphingosine and ceramide (d36:1) were, however, detected indicating that they are 193 
acquired from the media. Likewise, SM may also be derived from the media since there is no 194 
evidence that Leishmania synthesize SM, although they do possess SMase which has been shown to 195 
be essential in degrading host-derived SM to promote parasite survival, proliferation and 196 
virulence(40). The increase in SLs could indicate a stimulatory effect of miltefosine on biosynthesis or 197 
inhibition of a catabolic pathway, the latter seeming more likely since the mutant also accumulates 198 
higher levels of the two SLs detected (SM and ceramide d36:1 upon treatment (Figure 3).   199 
As in L. donovani, sterols were also increased by treatment in L. major wild type, though not in 200 
ΔLCB2 mutants. The identification of sterols poses a particular challenge since many in the pathway 201 
share identical masses. However, using the calculated LogP values it was possible to identify each 202 
based on their elution order in the LC-MS data, as shown in SI file 2. Figure 4 shows the ergosterol 203 
biosynthesis pathway and highlights observed increases in L. donovani after 5 h (blue arrows), 24 h 204 
(red arrows) and in L. major wild type after 5 h (green arrows) of miltefosine exposure. Trends were 205 
the same for both concentrations of the drug, except for fecosterol at the higher dose in L. donovani 206 
which was increased albeit not significantly.   207 
Although sterol differences were not observed with treatment in ΔLCB2 mutants (ST 7), comparison 208 
to the un-treated wild type revealed dramatic differences in sterol metabolism, particularly with 209 
respect to ergosterol and cholesterol. This alteration in sterol composition in the selection of the 210 
mutant is particularly noteworthy since it enables the mutant to survive without SL synthesis, while 211 
the change in sterol composition may stabilise membranes in the face of miltefosine treatment, 212 
emphasising the complex interplay between SL and sterol metabolism. As shown in the 213 
chromatographic peaks in Figure 4, ergosterol levels were significantly reduced (approximately 214 
halved p=5 ×10-14) in the ΔLCB2 relative to wild type whilst cholesterol levels were around 3-fold 215 
more abundant p=8 ×10-12. Cholesterol is probably scavenged in Leishmania(26).  Ergosterol was 216 
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significantly increased with treatment in the wild type and of much lower abundance in the mutant 217 
which exhibit a 3-fold reduced sensitivity to the drug. 5,7,22,24(28)-Ergostatetraenol, which 218 
precedes ergosterol in its synthetic pathway, is also dramatically more abundant in ΔLCB2 mutants 219 
compared to wild type, which suggests that the final step in ergosterol synthesis (catalysed by erg4) 220 
is diminished in the mutant. Two further sterols, which share the same mass as ergosterol, 221 
5,7,24(28)-Ergostatrienol and 5-dehydroepisterol, were observed in the mutant but were below the 222 
limit of detection in the wild type. Their accumulation may also occur due to the reduced production 223 
in ergosterol biosynthesis later in the pathway.  224 
ΔLCB2 Leishmania mutants are viable while the same enzyme is essential to African trypanosomes. 225 
This has been proposed to  be due to  Leishmania depending on ergosterol as its primary sterol 226 
rather than cholesterol as in T. brucei(29). However, since the ΔLCB2 mutant exhibits much higher 227 
cholesterol and lower ergosterol concentrations relative to wild type, the simplistic view of changes 228 
in cholesterol versus ergosterol appears to be inadequate to explain the essential nature of SL 229 
synthesis in T. brucei. Though the magnitude of this sterol balance is not as severe as in T. brucei, 230 
retained viability in the absence of SL synthesis is likely to be due to other reasons. As observed in 231 
the L.major ΔLCB2 mutants, ergosterol reduction has been reported in a strain of L. infantum 232 
resistant to 200 µM miltefosine compared to wild type(41), although the mechanism of resistance 233 
was reported to be associated to mutations in the miltefosine transporter. In L.donovani 234 
promastigotes, membrane sterol depletion has been correlated with reduced sensitivity to 235 
miltefosine(42). In that study the authors tested a hypothesis that lipid rafts could be involved in 236 
miltefosine action by destabilising these micro-domains through depletion of sterols using either 237 
methyl-β-cyclodextrin (MCD) or cholesterol oxidase (CH-OX). Sterol depletion showed no significant 238 
effects on the viability of either wild type or mutant, however MCD treatment significantly 239 
decreased the susceptibility of wildtype to miltefosine (around 2-fold) although CH-OX depletion 240 
caused no significant effect. Since MCD has less specificity in sterol extraction than CH-OX, MCD is 241 
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likely to deplete ergosterol and other sterols in addition to cholesterol, pointing to a possible link 242 
between ergosterol depletion and reduced miltefosine activity. Increases in ergosterol in L. donovani 243 
and L. major (wild type) co-ordinated with an increase in SLs reported here may also point towards a 244 
function of lipid micro-domain complexes of sterols and SLs(27, 29, 42) in miltefosine’s effects on 245 
the parasites. Apoptosis has been proposed as an effect of miltefosine in tumour cells relating to 246 
lipid micro-domains(43–45). Though the existence of apoptosis in Leishmania has been 247 
challenged(46), various indications point to miltefosine inducing an apoptosis-like death in 248 
L. donovai promastigotes(16).  It is clear that miltefosine treatment causes profound changes to the 249 
lipid content of Leishmania amastigotes and promastigotes and that alteration in lipid composition 250 
such as a loss of SL biosynthesis and an accompanying change in sterol metabolism, impact on this 251 
action of the drug.   252 
CONCLUSION 253 
A robust platform offering broad coverage of Leishmania metabolites using two complementary 254 
techniques was developed to study miltefosine MoA.  In addition to revealing miltefosine’s effects 255 
on internal metabolites and possible interference with membrane transport, many lipid species were 256 
shown to be perturbed by treatment and importantly SLs and sterols were found to increase. These 257 
findings, initially observed in L. donovani axenic amastigotes, were confirmed in L. major 258 
promastigotes for which a defined ∆LCB2 mutant, devoid of SL biosynthesis was available. These 259 
mutant parasites lacked SLs, other than those derived from the culture medium, and sterol 260 
metabolism was drastically altered compared with wild type. This lipidomic remodelling was 261 
associated with a 3-fold reduction in sensitivity to miltefosine. Coupled with the observation that 262 
sterol concentrations increase when both L. major and L. donovani wild type parasites were exposed 263 
to miltefosine, a major role for these lipids in miltefosine resistance and, perhaps, MoA is indicated. 264 
MATERIALS AND METHODS 265 
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Experimental design 266 
In order to define the optimal protocol for sampling/quenching/extracting/analysing metabolites 267 
from L. donovani axenic amastigotes, a two-stage experiment was designed that i) allowed a 268 
reproducible global profile of metabolites to be obtained and ii) allowed the execution of the 269 
optimised protocol in the exploration of miltefosine MoA. It was necessary to optimise parasite 270 
seeding densities and harvesting numbers to work with 5 h and 24 h time-points to obtain sufficient 271 
biomass for metabolomics analyses, while also ensuring log phase of growth (metabolic steady state) 272 
in parasites at the time of harvesting. Parasites were always seeded from log phase cultures to 273 
minimise lag phase (particularly important at 5 h). Optimal seeding densities were determined as 274 
6.67 × 106 parasites/mL for samples to be harvested at 5h and 1.33 × 106 parasites/mL for samples to 275 
be harvested at 24h. Details of the method development are given in full in SI. 276 
Chemicals and reagents 277 
The axenic culture medium used in all experiments was prepared from one batch prepared ‘in-278 
house’ as described in Peña I. et al.(2). The culture medium used for L. major wild type and was 279 
Schneider’s Drosophila media (Sigma Aldrich) supplemented with heat inactivated foetal bovine sera 280 
(15%). All methanol used was HPLC-grade and formic acid was analytical grade. These chemicals in 281 
addition to formaldehyde solution and PBS were purchased from Sigma-Aldrich. Ultrapure water 282 
was obtained using a Milli-Qplus 185 system (Millipore, Bilerica, MA, USA). 283 
Sample collection and quenching of metabolism 284 
L. donovani strain 1S2D (WHO designation: MHOM/SD/62/1S-CL2D)(47) was cultured by cycling 285 
between promastigotes and axenic amastigotes using protocols from prior work(2). Briefly, the 286 
promastigote form was grown at 29 °C and amastigote forms were grown at 37 °C with 5 % CO2 in 287 
different media adapted from De Rycker, et al.(48). For experiments with miltefosine, three T75 288 
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flasks were prepared (with 30 mL culture at the appropriate densities for 5h or 24 h as described 289 
above) for each condition: non-treated parasites, parasites treated with the lower dose of 290 
miltefosine (4.47 μM) and parasites treated with the higher dose of miltefosine (13.41 μM).  291 
At the time of sample harvesting, culture from each flask was divided equally into two 15 mL Falcon 292 
tubes resulting in six replicate samples for each condition. Before the division, 50 µL of each culture 293 
was collected into Eppendorf tubes to which 50 µL formaldehyde was added and samples were 294 
stored at 4 °C to be counted later in order to record the exact number of parasites from each flask at 295 
the time of harvesting. At the time of harvesting and throughout the subsequent processes, samples 296 
were maintained at 4 °C.  297 
After collection of culture, each sample was centrifuged at 1500 × g at 4 °C for 15 min after which 298 
medium was decanted and parasites were washed in 2 mL PBS (maintained at 4 °C), then samples 299 
were transferred to 2 mL Eppendorfs. From each sample, 10 µL was taken and fixed with 10 µL of 300 
formaldehyde and stored at 4 °C to be counted later in order to record the exact number of 301 
parasites in each sample immediately before quenching. Samples were subsequently centrifuged at 302 
1500 × g at 4 °C for 15 min, PBS was decanted and 200 µL ice cold methanol was added to each 303 
sample that were immediately stored at -80 °C until extraction and metabolomics analysis. Figure 1S 304 
of Supplementary Information shows the workflow for the developed method for sampling. 305 
Leishmania major parasites (MHOM/IL/81/Friedlin; FV1 strain) and a mutant in which the catalytic 306 
subunit of serine palmitoyltransferase had been deleted by homologous recombination (∆LCB2)(31) 307 
were cultured as log phase promastigotes at 26°C. Samples were prepared for metabolomics as 308 
described for L. donovani with the appropriate miltefosine doses as described above, except 10 μM 309 
or 30 μM were used for the lower and higher dose of miltefosine respectively. 310 
Metabolite extraction 311 
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Extraction blanks were prepared following all stages of extraction. On the day of analyses, 312 
metabolites were extracted and supernatants analysed by LC-MS (and for all L. donovani samples in 313 
CE-MS too). Samples were prepared by first evaporating extracts to dryness using a speed vacuum 314 
concentrator (Eppendorf, Hamburg, Germany), after which 200 mg of 425-600 µm acid-washed glass 315 
beads were added. Then to L. donovani samples, 575 µL of 100 % methanol were added, before 316 
which samples were vortex mixed for 10 min and placed in a tissue lyzer for 30 min at 50 Hz. Finally 317 
samples were centrifuged at 16,000 × g at 4 °C for 10 min and 80 µL of the resulting supernatants 318 
were collected into LC-MS vials to be analysed directly. To the remaining samples (for CE-MS), 319 
165 µL water were added and all vortex mixed for 30 min then centrifuged at 16,000 × g at 4 °C for 320 
10 min, before being evaporated to dryness and re-suspended in 100 µL of water containing 0.2M 321 
methionine sulfone (internal standard) and 0.1mM formic acid was added to each. QC samples for 322 
LC-MS and CE-MS were prepared by collecting 10 µL from each sample into a single pool. For L. 323 
major, only LC-MS extracts were prepared and therefore after evaporation, 120 mg of 425-600 µm 324 
acid-washed glass beads and 350 µL methanol were added for extraction and 270 µL of the resulting 325 
supernatants following extraction were collected into LC-MS vials to be analysed directly, from 326 
which 30 µL was subtracted from each into a pool.  327 
Analysis of extracts by LC-MS and CE-MS 328 
For each analysis, extraction blanks were injected at the start of the analysis followed by eight 329 
injections of the QC sample in order to ensure system stability, before the injection of samples 330 
analysed in a random order with the QC injected after every sixth sample until the end of the 331 
analysis. All instrumentation was from Agilent Technologies. For LC-MS, a 1290 infinity LC equipped 332 
with reverse-phase column (Zorbax Extend C18 50 × 2.1 mm, 3 μm; Agilent) was coupled to a 6550 Q-333 
TOF MS with electrospray ionisation source and operated in both positive and negative mode. For 334 
CE-MS the instrument consisted of a 7100 CE coupled to a 6224 TOF MS operated in positive mode. 335 
Details of the analytical procedures based on previously published methods(49, 50) are given in SI.  336 
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Data analysis and feature identification  337 
Data from both platforms were processed using recursive analysis in Mass Hunter Profinder 338 
(B.06.00, Agilent) software as detailed in SI. Data were reprocessed considering ions such as [M+H]+ 339 
and [M+Na]+, neutral water loss and the maximum permitted charge state was double. Alignment 340 
was performed based on m/z and RT similarities within the samples. Parameters applied were 1 % 341 
for the RT window and 20 ppm for mass tolerance.  342 
Data treatment consisted of filtering based on quality, following the same procedure for each 343 
dataset (L. donovani: LC-MS positive ion mode, LC-MS negative ion mode, CE-MS positive ion mode; 344 
L. major: LC-MS positive ion mode, LC-MS negative ion mode).  Data were filtered based on quality 345 
using a quality assurance procedure described previously (QA+)(51). This involved retaining features 346 
present in QCs at a rate of 80 % or absent in QCs (defined as presence < 20 %). For features present 347 
in QC samples, only those with RSDs < 30 % were kept and for those absent, RSD was not calculated. 348 
Then, for each comparison separately (5h, or 24h, wild type or ∆LCB2 mutant), features were further 349 
filtered to keep only those present in at least five out of six of the replicates from one of the groups 350 
simultaneously compared (resulting in a slightly different, but relevant dataset for each comparison). 351 
For L. donovani multivariate analysis was employed firstly to observe the stability in each analysis 352 
(LC-MS in positive and negative ionisation modes or CE-MS) as a whole and then for each time point 353 
separately to investigate the effect of the drug on the parasite metabolome. To probe specific 354 
questions on the effect of miltefosine at different time points or doses, fold-changes and p-values 355 
were calculated in order to assess the degree of significance of any difference observed in the raw 356 
data.  357 
All significantly different metabolite features between un-treated and treated parasites at any dose, 358 
determined by determined by a p-value <0.05 (Student’s two-tailed t-test, n=6 per group) and a fold 359 
change, ±1.5 were identified. Identification was performed searching m/z against Metlin 360 
 o
n
 M
arch 20, 2018 by SW
ETS SUBSCRIPTIO
N SERVICE
http://aac.asm
.org/
D
ow
nloaded from
 
16 
 
(http://metlin.scripps.edu) and lipidMAPS (http://lipidMAPS.org), considering the same adducts as 361 
those described for data re-processing. Annotations were assigned to m/z values for metabolite 362 
features considering i) mass accuracy (maximum mass error 10ppm); ii) isotopic pattern distribution; 363 
iii) possibility of cation and anion formation and iv) adducts formation. This method of enhanced 364 
annotation was based on our previously published work(49). Where possible, identifications were 365 
compared by retention time order to standards analysed in-house. For CE-MS, definitive 366 
identifications were made for a number of metabolites through analysis of authentic standards 367 
analysed under the same conditions as the experiment, whereby samples were analysed again 368 
followed by the same samples spiked with authentic standards to prove the identity.  369 
All data analysed during this study are included in this published article and in the supplementary 370 
tables (Supplementary Information files). 371 
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Table 1: Metabolites identified in Leishmania donovani axenic amastigotes and significantly affected by miltefosine. 539 
 540 
Identification (MSI level 1) m/z 
Migration 
Time 
5 hours 24 hours 
t-test Fold change t-test Fold change 
LD  HD LD  HD  LD HD LD  HD 
Acetyl-carnitine 204.1232 13.93 3.71E-02 2.30E-05 1.1 1.5 1.28E-03 4.37E-04 1.5 2.4 
Adenosine 268.1042 15.23 NS NS     8.03E-04 4.22E-04 3.7 57.3 
Alanine 90.0552 13.95 6.86E-03 2.47E-03 1.3 1.4 2.49E-05 1.33E-06 1.7 5.4 
Argininic acid 176.1032 14.19 1.32E-02 2.57E-04 1.2 1.6 9.30E-08 2.85E-08 2.8 6.8 
Asparagine 133.0612 15.89 9.15E-03 2.60E-02 1.4 1.3 NS 4.30E-02   1.7 
Betaine 118.0862 17.09 1.49E-02 NS 1.2   NS 4.51E-03   1.2 
Choline 104.1072 10.92 1.35E-05 NS 1.5   3.24E-04 NS 1.4   
Citrulline 176.1032 16.68 9.08E-03 NS 1.3   1.47E-06 1.39E-05 1.6 1.4 
Isoleucine 132.1022 15.52 2.56E-02 1.83E-04 1.3 3.0 1.39E-06 6.56E-06 2.1 4.2 
Leucine 132.1022 15.65 4.61E-02 5.08E-03 1.3 1.8 3.91E-03 4.15E-04 1.9 3.2 
Lysine 147.1122 11.14 5.50E-04 5.73E-05 1.6 2.7 1.29E-05 1.24E-06 2.1 2.9 
Pipecolic acid 130.0862 15.62 6.08E-04 5.05E-04 1.8 1.8 3.78E-03 9.20E-07 1.3 4.3 
Valine 118.0862 15.28 2.95E-03 5.84E-06 1.3 2.5 4.36E-06 3.20E-07 2.1 3.6 
Glutamic acid 148.0682 16.51 NS 3.22E-05 1.1 1.3 4.18E-04 2.46E-09 1.2 4.7 
Aspartic acid 134.0452 17.27 NS NS     6.56E-03 1.64E-07 1.2 3.0 
Creatine 132.0772 13.79 NS NS     2.42E-04 1.21E-04 1.9 2.5 
Histidine 156.0772 11.72 NS 2.49E-03   1.8 1.85E-06 1.55E-06 2.3 11.0 
Arginine 175.1192 11.44 NS 9.87E-03   1.3 2.10E-08 1.18E-09 2.4 6.0 
Proline 116.0702 11.04 NS 1.39E-02   2.1 5.35E-06 6.07E-06 4.0 40.2 
Ornithine 133.0972 11.06 NS 1.45E-02   2.0 7.53E-06 7.94E-06 4.2 34.6 
Adenine 136.0612 12.12 NS NS     4.06E-03 1.90E-03 4.1 17.5 
Thiamine 265.1122 10.67 NS 2.19E-02   1.6 1.13E-02 3.73E-02 2.0 2.0 
Methionine 150.0592 16.17 NS NS     4.43E-05 7.76E-05 2.2 6.4 
S-adenosylhomocysteine 385.1292 13.73 NS 3.87E-02   1.5 2.68E-03 7.44E-05 1.8 NC 
Trans-4-Hydroxyproline 132.0652 17.99 NS NS     1.09E-05 1.25E-05 1.3 1.4 
Phenylalanine 166.0872 16.65 NS NS     6.82E-03 8.71E-03 1.4 2.0 
Carnitine 162.1122 13.30 NS 2.15E-03   1.2 9.26E-08 1.93E-08 1.5 3.7 
 541 
Metabolites identified in CE-MS analysis of Leishmania donovani axenic amastigotes as being significantly 542 
affected by miltefosine treatment in different doses/time-points. All identifications have been determined 543 
at MSI level 1, as defined by the analysis of authentic standards. Calculated p-values (Student’s two-tailed t-544 
test (n=6 per group) and fold changes are shown for the lower dose (LD: 4.47 μM) or higher dose (HD: 13.41 545 
μM) versus the un-treated samples at the respective time-point. Where p-values were not significant (NS: p 546 
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> 0.05), there were no fold changes to report. Fold changes are absolute; all are decreases except those 547 
highlighted in grey which are calculated increases with miltefosine with respect to un-treated controls. 548 
Figures 549 
 550 
Figure 1: Effect of miltefosine on arginine metabolism observed in L. donovani axenic amastigotes after 24h 551 
of exposure at the lower dose of 4.47 µM. Plots show peak area abundances detected in samples: un-552 
treated parasites in blue, parasites treated with 4.47 µM miltefosine in red.  553 
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554 
Figure 2: Effect of miltefosine on the SL biosynthetic pathway observed in L. donovani axenic amastigotes 555 
after 24h of exposure at the lower dose of 4.47 µM. Plots show peak area abundances for key SLs detected 556 
in samples: un-treated parasites in blue, parasites treated with 4.47 µM miltefosine in red. Sphinganine 557 
shown is C16 form, Ceramide shown is 34:1 form, Sphingosine shown is 18:1 form and ceramide phosphate 558 
shown is 26:1 form. Plots show trends representative of all detected SLs of their type. For full list of detected 559 
SLs, refer to Supplementary Table 3. 560 
561 
Figure 3: Fold changes in abundance of all SLs detected in L.donovani axenic amastigotes and / or L.major 562 
promastigotes, comparing treated parasites to un-treated parasites. Lower dose and higher dose data are 563 
 o
n
 M
arch 20, 2018 by SW
ETS SUBSCRIPTIO
N SERVICE
http://aac.asm
.org/
D
ow
nloaded from
 
27 
 
shown for each, corresponding to 4.47 μM and 13.41 μM respectively for L.donovani and 10 μM and 30 μM 564 
respectively for L.major. SLs that were not detected in a certain dataset are marked with ‘ND’, while X 565 
denotes complete absence in drug treated parasites and presence in un-treated parasites. 566 
567 
Figure 4: Ergosterol biosynthesis pathway. Sterols increased, decreased or detected but with no change as a 568 
response to miltefosine exposure are shown on the pathway (L .donovani axenic amastigotes with 5h drug 569 
exposure in blue; L. donovani axenic amastigotes with 24h drug exposure in red; L. major wild type 570 
promastigotes in green). In all cases, trends were seen for both low and high concentrations of miltefosine 571 
treatment. Chromatographic peaks shown for ergosterol, cholesterol, 5,7,24(28)-Ergostatrienol and 5-572 
dehydroepisterol in L. major wildtype (black trace) and ΔLCB2 mutants (red trace) to highlight the 573 
differences in sterol profiles between them. 5,7,24(28)-Ergostatrienol and 5-dehydroepisterol share the 574 
same logP and therefore it is not possible to distinguish which peak (9.8-9.9 min or 10.2-10.3 min) these 575 
sterols correspond to.  576 
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